Aimee Newsom
Family · Winnsboro, SCNPI 1043695570
Payments from drug & device makers
Across 293 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$785
- AstraZeneca$704
- Dexcom, Inc.$422
- Lilly USA, LLC$360
- Amgen$338
- AbbVie$264
- plus $2K from 35 others
What the payments were for
- Food & beverage$4,76298%
- Education$1102%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $785 |
| AstraZeneca(2 entities) | 39 | $704 |
| Dexcom, Inc. | 14 | $422 |
| Lilly USA, LLC | 27 | $360 |
| Amgen | 21 | $338 |
| AbbVie(2 entities) | 24 | $264 |
| Astellas Pharma US Inc | 6 | $177 |
| Pfizer | 10 | $165 |
| Xeris Pharmaceuticals, Inc. | 5 | $153 |
| Amarin Pharma, Inc. | 8 | $120 |
| Esperion Therapeutics, Inc. | 6 | $109 |
| Novartis | 6 | $97 |
| Bayer | 6 | $97 |
| GSK | 6 | $94 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $86 |
| Corcept Therapeutics | 4 | $74 |
| Vivus LLC | 5 | $74 |
| Merck | 5 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $60 |
| Exact Sciences | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $57 |
| Sumitomo Pharma America, Inc. | 2 | $55 |
| Daiichi Sankyo Inc. | 3 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $44 |
| Optinose US, Inc. | 3 | $41 |
| Abbott | 3 | $40 |
| Edwards Lifesciences | 2 | $34 |
| Lundbeck LLC | 1 | $32 |
| Nestle Healthcare Nutrition Inc. | 2 | $26 |
| Abiomed | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Renalytix AI, Inc. | 1 | $21 |
| Vital Connect, Inc | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Stryker | 1 | $16 |
| Biogen | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Vistapharm, Inc. | 1 | $13 |
| Seqirus USA Inc | 1 | $13 |
How this compares
$4,872 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $110,981 |
| FarxigaDapagliflozin Propanediol | 57 | $54,177 |
| EliquisApixaban | 63 | $53,963 |
| MounjaroTirzepatide | 42 | $50,846 |
| TrulicityDulaglutide | 28 | $42,878 |
| MyrbetriqMirabegron | 44 | $33,244 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $26,640 |
| JardianceEmpagliflozin | 16 | $26,211 |
| XareltoRivaroxaban | 18 | $17,784 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $14,767 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 42 | $9,370 |
| VascepaIcosapent Ethyl | 16 | $9,269 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $8,579 |
| NamzaricMemantine Hcl/Donepezil Hcl | 13 | $7,240 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $6,538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $785 | $110,98170 claims |
| Lilly USA, LLCMounjaro, Trulicity | $360 | $93,72470 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $704 | $68,94471 claims |
| PfizerEliquis | $165 | $53,96363 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $177 | $38,98355 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $13 | $31,53727 claims |
| GSKShingrix, Arexvy | $94 | $13,90056 claims |
| MerckJanumet | $62 | $8,57916 claims |
| AbbVieNamzaric | $264 | $7,24013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.
Other family in Winnsboro
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.